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Abstract Modern neuropathology serves a key function
in the multidisciplinary management of brain tumor
patients. Owing to the recent advancements in molecular
neurooncology, the neuropathological assessment of brain
tumors is no longer restricted to provide information on a
tumor’s histological type and malignancy grade, but may
be complemented by a growing number of molecular tests
for clinically relevant tissue-based biomarkers. This arti-
cle provides an overview and critical appraisal of the
types of genetic and epigenetic aberrations that have
gained signiﬁcance in the molecular diagnostics of glio-
mas, namely deletions of chromosome arms 1p and 19q,
promoter hypermethylation of the O6-methylguanine-
methyl-transferase (MGMT) gene, and the mutation status
of the IDH1 and IDH2 genes. In addition, the frequent
oncogenic aberration of BRAF in pilocytic astrocytomas
may serve as a novel diagnostic marker and therapeutic
target. Finally, this review will summarize recent mech-
anistic insights into the molecular alterations underlying
treatment resistance in malignant gliomas and outline
the potential of genome-wide proﬁling approaches for
increasing our repertoire of clinically useful glioma
markers.
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Introduction
Gliomas are the most frequent primary brain tumors and
include a variety of different histological tumor types and
malignancy grades. Although the cellular origin of gliomas
is still unknown, experimental data in mice suggest an
origin from neoplastically transformed neural stem or
progenitor cells. However, histological classiﬁcation of
gliomas essentially relies on morphological similarities of
the tumor cells with non-neoplastic glial cells and the
presence of particular architectural features; thereby, most
gliomas can be classiﬁed as astrocytic, oligodendroglial,
mixed oligo-astrocytic or ependymal tumors according to
the criteria of the World Health Organization (WHO)
classiﬁcation of central nervous system tumors [81]. The
astrocytic tumors are most common and include the most
malignant type of glioma, the glioblastoma. Although
ependymal tumors are often relatively circumscribed, most
astrocytic, oligodendroglial and oligoastrocytic tumors in
adults diffusely inﬁltrate the adjacent brain tissue [24].
Therefore, these latter neoplasms are often designated as
‘diffuse gliomas’. In contrast, the most frequent glioma in
children, the pilocytic astrocytoma, is a low-grade (WHO
grade I) neoplasm that usually shows limited inﬁltrative
growth and does not progress to malignancy. In addition to
these common glioma types, a number of rare, mostly low-
grade malignant glioma entities and variants as well as
several types of mixed glial and neuronal tumors may be
observed, in particular in children and young adults.
However, detailed discussion of these rare tumors is
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about molecular alterations in these tumors is still limited
and does not yet contribute to their clinical management.
Diffuse gliomas are one of the most devastating cancers
because they often show locally aggressive behavior and
cannot be cured by current therapies. Moreover, low-grade
(WHO grade II) diffuse gliomas have a strong tendency for
malignant progression to anaplastic (WHO grade III) gli-
omas and eventually secondary glioblastomas (WHO grade
IV). An accurate distinction between the different glioma
entities is important because of its strong prognostic and
therapeutic implications. So far, histopathology is the gold
standard for the typing and grading of gliomas. However,
histological classiﬁcation of gliomas is not trivial and
associated with signiﬁcant interobserver variability. Fur-
thermore, the clinical behavior of individual tumors of a
speciﬁc histopathological entity may substantially differ.
Thus, additional markers are needed for a reﬁned and more
objective glioma classiﬁcation, a better prediction of
prognosis and a tailored therapeutic decision-making.
Like cancer in general, gliomas develop as a result of
genetic alterations that accumulate with tumor progression.
Knowledge of the genetic alterations in the various types
and malignancy grades of gliomas has drastically increased
Fig. 1 Summary of most frequent molecular alterations in astrocytic,
oligodendroglial, and oligoastrocytic gliomas. Primary glioblastomas,
the most common gliomas in adults, show complex chromosomal,
genetic, and epigenetic alterations targeting genes involved in
important cellular pathways, namely the receptor tyrosin kinase/
mitogen-activated protein kinase/phosphoinositol 3-kinase pathway
(e.g. EGFR, MET, PDGFRA, ERBB2, NF1, PTEN, PIK3R1, PI3KCA,
CTMP), the p53 pathway (e.g. TP53, p14
ARF, MDM2, MDM4), and the
pRb1 pathway (e.g. CDKN2A, CDKN2B, CDK4, CDK6, RB1). In
addition, primary glioblastomas frequently show monosomy 10,
trisomy 7 and gains of 19q and 20q. Diffuse WHO grade II and III
astrocytic, oligodendroglial andoligoastrocytic gliomasand secondary
glioblastomas frequently carry mutations in IDH1 or IDH2, suggesting
that they share a common, yet to be deﬁned cell of origin. Diffuse
astrocytic gliomas often carry additional TP53 mutations, while
oligodendroglial tumors are characterized by 1p/19q deletion. Most
oligoastrocytomas have either of these alterations. Molecular changes
associated with progression to anaplastic glioma include 9p losses and
inactivation of the CDKN2A, p14
ARF and CDKN2B genes on 9p21 as
well as other changes, while progression to secondary glioblastoma is
associated with frequent loss of 10q and DCC loss of expression
among others. The majority of pilocytic astrocytomas are character-
ized by duplication/fusion or point mutation of the BRAF gene on
7q34, while other genomic aberrations are rare
568 Acta Neuropathol (2010) 120:567–584
123over the past years (Fig. 1). Brieﬂy, mutation of the tumor
suppressor gene TP53 (located at 17p13.1) and loss of
heterozygosity on chromosome arm 17p are found in more
than half of the WHO grade II diffuse astrocytomas. In
addition, gains on the long arm of chromosome 7 are often
present. In contrast, oligodendroglial tumors frequently
show combined losses of the short arm of chromosome 1
and of the long arm of chromosome 19. Oligoastrocytic
neoplasms are genetically either related to oligodendroglial
or to astrocytic tumors. Only recently, mutation of the
isocitrate dehydrogenase 1 (IDH1) gene, or less commonly
of the related IDH2 gene, have been identiﬁed in the vast
majority of WHO grades II and III astrocytic, oligoden-
droglial, and oligoastrocytic gliomas [2, 137] suggesting a
common initiating event in these histologically and bio-
logically diverse glioma types. Anaplastic (WHO grade III)
astrocytomas often carry additional, progression-associated
genetic changes, such as losses of the tumor suppressor
genes CDKN2A, CDKN2B, and p14
ARF on 9p21 and
deletions on chromosomes 6, 11p, 22q, and others. More-
over, CDK4 or CDK6 ampliﬁcation or inactivating
alterations of RB1 are detectable in a subset of anaplastic
gliomas, mainly anaplastic astrocytomas. Glioblastomas
show complex chromosomal and genetic alterations that
lead to inactivation of various tumor suppressor genes, as
well as aberrant activation of proto-oncogenes [18, 120].
The vast majority of glioblastomas present de novo in
elderly patients with a short clinical history. These primary
glioblastomas are characterized by a distinct pattern of
genetic aberrations when compared with the less common
secondary glioblastomas, which develop by progression
from pre-existing lower grade gliomas [93]. In particular,
primary glioblastomas show frequent EGFR ampliﬁcation
and PTEN mutation but lack IDH1 mutation, while sec-
ondary glioblastomas are characterized by frequent
mutations in the TP53 and IDH1 genes, but lack EGFR
ampliﬁcation [73, 93] (Fig. 1). At the chromosomal level,
primary glioblastomas are distinct from secondary glio-
blastomas by the frequent trisomy of chromosome 7 and
monosomy of 10, as well as frequent gains of chromosome
arms 12p, 19q, and 20q [120]. Despite these differences,
however, most of the genetic alterations in primary and
secondary glioblastomas can be assigned to a common set
of functional pathways [18] (Fig. 1; see also below).
From the identiﬁcation of molecular changes to novel
diagnostic, prognostic, and predictive biomarkers
Severalofthemolecularalterationsdetectedingliomasmay
have diagnostic and/or prognostic implications, as they are
associated with histologically deﬁned tumor types or
malignancy grades. However, for most of the molecular
changes this does not justify a designation as glioma bio-
marker, because biomarkers should provide unique
diagnostic, prognostic, or predictive information exceeding
that reached by mere histological classiﬁcation. A mean-
ingful diagnostic biomarker should be helpful in the
classiﬁcation of tumors with ambiguous histological fea-
tures or allow for a clinically useful subdivision of tumors
within a given histological tumor type. A useful prognostic
biomarker should correlate with disease-free and overall
survival,ideallyprovidinginformationbeyondthatobtained
by established prognostic parameters, such as patient age,
clinical performance status, extent of resection, and WHO
grade. A predictive biomarker, ﬁnally, should provide
valuable information on the response to a given therapy,
which will help to stratify patients into distinct therapeutic
groups to allow for the optimal (‘‘personalized’’) treatment.
In this regard, the number of molecular biomarkers in
Table 1 The four markers that are presently the most relevant for molecular diagnostics of gliomas
Molecular marker Clinical signiﬁcance
MGMT promoter methylation Predictive for response of glioblastomas to alkylating chemotherapy
Associated with longer survival of glioblastoma patients treated with radiotherapy combined
with concurrent and adjuvant temozolomide
Prognostic in anaplastic glioma patients treated with radio- and/or alkylating chemotherapy
1p/19q deletion Associated with better prognosis in (oligodendro)glial tumor patients receiving adjuvant radio-
and/or chemotherapy
Not predictive for response to a particular type of therapy
IDH1/IDH2 mutation Diagnostic marker for diffuse WHO grade II and III gliomas as well as secondary
glioblastomas and associated with a better prognosis in these tumors
Rare in primary glioblastomas but when present associated with more favorable outcome
Not predictive for response to a particular type of therapy
BRAF duplication/fusion Diagnostic marker for pilocytic astrocytomas, helpful to distinguish these from diffuse
astrocytomas
Prognostic signiﬁcance within the group of pilocytic astrocytoma patients unknown
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combined deletions of the chromosome arms 1p and 19q in
oligodendroglial tumors, MGMT hypermethylation in glio-
blastomas and anaplastic gliomas, IDH1 and IDH2
mutations in diffuse gliomas, as well as BRAF aberrations in
pilocyticastrocytomas(Table 1).Moredetailedinformation
on the respective testing methods and the information con-
veyed by these markers is provided in the subsequent
paragraphs of this review. In addition, we will review some
of the recent advancements concerning the understanding of
the biological mechanisms of treatment resistance in high-
grade gliomas, such as treatment-associated somatic muta-
tions of the mismatch repair gene MSH6 [15, 57, 139]. We
will also discuss the potential role of predictive testing for
responsiveness towards targeted therapies, such as the
assessment of the EGF receptor status in adult high-grade
gliomas or the BRAF status in pilocytic astrocytomas.
Combined deletion of chromosome arms 1p and 19q
as prognostic marker for oligodendroglial tumor
patients
Loss of 1p and 19q is the genetic hallmark of oligoden-
droglial tumors [68, 81]. Frequencies reported vary due to
interobserver variability in the distinction of oligoastrocy-
tomas from oligodendrogliomas on the one hand and
astrocytomas on the other, as well as the techniques used
and the loci investigated [68]. Overall, losses of 1p and 19q
are detected in up to 80% of oligodendrogliomas (WHO
grade II) and approximately 60% of anaplastic oligoden-
drogliomas (WHO grade III), whereas 30–50% of
oligoastrocytomas, 20–30% of anaplastic oligoastrocyto-
mas, and\10% of diffuse astrocytic gliomas, including the
glioblastomas, carry this aberration. The observation that
usually both 1p and 19q are completely lost is explained by
an unbalanced translocation t(1;19)(q10;p10), of which the
1p–19q derivative is lost, whereas the 1q–19p derivative is
retained during cell replication [42, 62]. There is a strong
association between 1p/19q codeletion and classical oli-
godendroglial features on histology (e.g., perinuclear halo
and chicken-wire vascular pattern). However, morphology
alone cannot predict the 1p/19q status [40, 109] and up till
now the diagnosis of oligodendroglial neoplasms is based
on the morphological criteria [81].
In 1998, it was ﬁrst reported that 1p (and combined 1p/
19q) loss predicts better response to chemotherapy and
longer survival in anaplastic oligodendroglioma patients
[17]. Since then, many subsequent studies have been per-
formed, including three prospective randomized phase III
trials that corroborated 1p/19q deletion as a powerful
prognostic marker in patients with WHO grade III gliomas.
Importantly, these studies also indicated that the prognostic
power was independent of the type of adjuvant therapy, that
is radiotherapy, chemotherapy or combined radio-/chemo-
therapy [16, 122, 135]. Nevertheless, discussion remains
regarding the predictive (response to therapy) versus
prognostic (independent of therapy) nature of this marker.
Retrospective data on oligodendroglial tumor patients not
receiving any radio- or chemotherapy after their initial
surgical treatment revealed that 1p/19q loss was not asso-
ciated with longer progression-free survival [131]. These
data would suggest that 1p/19q loss characterizes a group of
gliomas that is more sensitive to genotoxic therapy in
general, i.e., radio- and alkylating chemotherapy, and, when
treated, are associated with signiﬁcantly longer survival.
Given the undisputed prognostic signiﬁcance of 1p/19q
loss in oligodendroglial tumor patients receiving adjuvant
therapy, many institutions have now established diagnostic
testing for this aberration. However, while 1p/19q loss is
associated with more favorable prognosis of patients
receiving adjuvant treatment, it needs to be emphasized that
this marker is of limited help for making treatment deci-
sions, such as radio- versus chemotherapy. One should also
be aware that the prognostic relevance of 1p/19q loss may
be less pronounced in the presence of other, prognostically
unfavorable genetic alterations [121]. In addition, different
types of 1p losses have been identiﬁed that have distinct
prognostic implications. For example, oligodendroglial
tumors carrying partial terminal or interstitial 1p losses are
associated with shorter patient survival when compared
with tumors with combined complete 1p/19q losses [33,
125] (Figs. 2, 3). Thus, molecular testing for 1p loss alone
by studying just distal markers on 1p36 may pick up cases
with less favorable prognosis when compared with oligo-
dendroglial tumors having a complete 1p/19q co-deletion.
Techniques used and the loci investigated for 1p/19q
testing differ widely among institutions, depending pri-
marily on the local expertise, existing laboratory equipment
and preferences of the neuropathologist and molecular
biologist involved (Table 2). Most commonly, loss of het-
erozygosity (LOH) [59, 102] or (ﬂuorescent) in situ
hybridization ((F)ISH) [47, 114] analyses are used. FISH
may bepreferredbypathologists astissue characteristics are
retained and no corresponding blood sample is required.
LOH analysis is most commonly available, but requires
comparative evaluation of the same set of loci in DNA
extracted fromnormalcellsofthepatient,usuallyperipheral
blood leukocytes. In addition, one should be aware that
‘‘pseudo-LOH’’ may be detected in some tumors displaying
allelic imbalances due to copy number gain rather than loss
of one allele, e.g. the frequent gain of 19q in primary glio-
blastomas. On the other hand, LOH analysis may be scaled
up more easily than FISH to the analysis of multiple loci
along each chromosome, which would help to avoid
detection of false-positive cases with partial 1p loss or
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123isolated 19q loss, and may even (partly) be automated in
larger molecular diagnostic units. Multiplex ligation-
dependent probe ampliﬁcation (MLPA) is another method-
ical option, asit allowsdetectionof copy numberchangesof
up to 45 loci in a single experiment [63, 64, 111]. Similar to
LOH analysis, MLPA only requires standard laboratory
facilities for PCR and capillary gel electrophoreses that are
widely available in molecular laboratories, but has the
advantage that a blood sample of the patient is not required.
MGMT hypermethylation as a prognostic or predictive
marker in malignant gliomas
The MGMT (O
6-methylguanine-DNA methyltransferase)
gene at 10q26 is frequently silenced by promoter
hypermethylation in diffuse gliomas and this has been
pinpointed as an epigenetic mechanism reducing MGMT
expression levels. Importantly, an association between
MGMT promoter methylation and the response of malig-
nant gliomas to alkylating chemotherapy using nitrosourea
compounds [32], temozolomide [48], or a combination of
both [53] has been observed. Based on MGMT promoter
methylation studies in a subpopulation of patients involved
in the EORTC/NCIC 22981/26981 trial [48, 117], Hegi
et al. reported that patients treated with radiotherapy and
temozolomide, and whose tumors had a methylated MGMT
promoter (which is seen in approximately 40% of primary
glioblastomas) survive signiﬁcantly longer when compared
with patients whose tumors lacked MGMT promoter
methylation [48]. In this land-mark paper, MGMT promoter
methylation did not signiﬁcantly inﬂuence survival in
patients treated with radiotherapy alone, suggesting that the
MGMT hypermethylation is predictive for favorable
response to chemotherapy.
Mechanistically, a predictive power of the MGMT pro-
moter status can be explained by the fact that MGMT
encodes a DNA repair protein that removes alkyl groups
from the O
6 position of guanine, which are introduced by
alkylating chemotherapeutic agents, such as temozolomide
[39]. Chemotherapy-induced DNA alkylation triggers
cytotoxicity and apoptosis, while high MGMT expression
in the tumor cells counteracts the cytotoxic effects and
thereby may cause treatment failure. MGMT promoter
methylation, however, impedes the transcription of the gene
resulting in a lack of MGMT mRNA and protein expression.
Glioblastoma cells with MGMT promoter hypermethylation
thus respond better to temozolomide, as they lack the ability
to repair the therapy-induced DNA damage.
Because the current standard of care for glioblastoma
patientsinvolvesradiotherapyplusconcomitantandadjuvant
temozolomide treatment [117], testing for MGMT promoter
methylation by means of methylation-speciﬁc polymerase
(MSP) chain reaction analysis or other methods is now
increasingly performed, not only for patients in clinical trials
but also in the routine diagnostic setting. The advantage of
MGMT methylation testing is that—if detected—a methyl-
ationsignalspeciﬁcallyresults fromtheneoplasticglial cells.
In contrast, attempts to replace MGMT promoter methylation
testing by a technically more simple immunohistochemical
analysis of MGMT protein expression did not prove reliable
for diagnostic purposes in most studies, as the immunohis-
tochemical assays may be disturbed by a variable content of
contaminating non-neoplastic cells, such as microglial cells,
lymphocytes, reactive astrocytes and vascular cells, which
retain MGMT expression also in MGMT-hypermethylated
gliomas [34]. The same applies for expression analyses based
on Western blotting or reverse transcription-PCR, as well as
biochemical assays detecting enzymatic activity. All these
Fig. 2 Different types of 1p and 19q losses as detected by array-
CGH. Genomic proﬁles were obtained using tiling-resolution arrays
containing 32,447 human BAC clones. Proﬁles are shown for
chromosomes 1 and 19. On the X axis, BACs are aligned according
to their physical mapping positions from the 1p telomere to the 1q
telomere (n = 2,365) and from the 19p telomere to the 19q telomere
(n = 735). On the the Y axis, the log2-transformed and normalized
test:reference intensity ratios [‘‘2Log(T/R)’’]) are represented. Cen-
tromeric and heterochromatic regions are not evaluated using array-
CGH resulting in absence of ratios (i.e. spots) in these regions and
thereby visually separating the p-arm from the q-arm. Losses detected
are indicated by a bar shown on the bottom of the ratio proﬁles,
representing a complete chromosomes 1p and 19q loss (a), a loss of
1p11-p31.1, and 19q13.31-19qter (b), and a loss of 1pter-1p31.2 and
19q13.32-19qter (c)
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neoplastic cells in the investigated tissue homogenates.
Nevertheless, several studies reported on signiﬁcant prog-
nosticassociationsusingsuchassaysongliomatissues[7,22,
61, 78].
Although data from the EORTC/NCIC 22981/26981 trial
[80] and another large prospective patient cohort [132]
found that MGMT promoter methylation was predictive for
longer survival only in those patients who received tem-
ozolomide, a recent paper reported that MGMT promoter
methylation is also predictive of response to radiotherapy
and linked to longer survival in the absence of adjuvant
chemotherapy [104]. Although this association is somewhat
debatable in glioblastomas, prospective trials on anaplastic
(WHO grade III) gliomas clearly indicated a prognostic role
of MGMT promoter methylation independent from the type
of adjuvant treatment, i.e., alkylating chemotherapy or
radiotherapy [123, 135]. The reason for a prognostic role of
MGMT promoter methylation in patients just receiving
radiotherapy remains unclear,and is rather unexpected from
a functional point of view. One may speculate that the
strong association of MGMT hypermethylation with 1p/19q
codeletion [9, 88, 124] and IDH1 mutation [108] (Fig. 3)
may reﬂect a global molecular constellation in anaplastic
gliomas that per se is associated with higher sensitivity to
cytotoxic therapy and more favorable outcome. Even fur-
ther, the MGMT-hypermethylated anaplastic gliomas may
belong to a group of gliomas characterized by multiple
hypermethylated genes [91], potentially including yet
unknown genes mediating radioresistance.
Similar to the ﬁndings in adult glioma patients, MGMT
promoter methylation [110], and reduced MGMT protein
expression [100] have been reported to be associated with
longer survival of pediatric malignant glioma patients. In
ependymal tumors, MGMT promoter methylation is less
common when compared with diffuse astrocytic and oligo-
dendroglial tumors [13, 74]. Other malignant brain tumors,
such as medulloblastomas [31] and anaplastic meningiomas
[12] rarely demonstrate MGMT promoter methylation.
Technical aspects of MGMT promoter methylation
testing
A number of different methods are currently in use to assess
the MGMT promoter methylation status in patient samples,
for review see [133]; (Table 2). The most commonly
employed method, and also the technique originally
described to convey the relevant clinical information, is
methylation-speciﬁc PCR analysis [48, 52]. This technique
makes use of primers that speciﬁcally amplify fragments
from either the methylated or the unmethylated sodium
bisulﬁte-modiﬁed DNA sequence. To make the primers
discriminative between bothsequences,they are designed to
contain a maximum number of CpG sites that differ in their
sequence between methylated and unmethylated bisulﬁte-
modiﬁed DNA. PCR products can then subsequently be
Fig. 3 Distribution of the four clinically relevant molecular altera-
tions according to glioma entity. Colored squares indicate that the
particular aberration is frequent in the respective tumor entity, i.e.,
usually detectable in 40% or more of the cases. Uncolored squares
indicate that the aberration is rare in the respective tumor entity, i.e.,
usually restricted to\10% of the cases (except for MGMT promoter
methylation being reported in approximately 20% of the pilocytic
astrocytomas). Note that oligodendrogliomas and anaplastic oligo-
dendrogliomas are characterized by the frequent coincidence of 1p/
19q deletions, IDH1 or IDH2 mutation and MGMT promoter
methylation (red squares). The same applies for oligoastrocytic
tumors, although the frequency of 1p/19q deletion is less common
when compared with ‘‘pure’’ oligodendrogliomas, also depending on
the stringency of the histological classiﬁcation used for mixed
gliomas. IDH1 mutation and MGMT promoter methylation is frequent
in diffuse astrocytomas, anaplastic astrocytomas and secondary
glioblastomas (green squares). In contrast, primary glioblastomas
rarely carry 1p/19q deletions and IDH1 mutations, while MGMT
promoter methylation is found in approximately 40% of the cases
(blue square). Pilocytic astrocytomas are uniquely characterized by
BRAF alterations in more than 60% of the cases (orange square)
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terms of an all or nothing signal. Alternatively, MSP can be
performed quantitatively using real-time or TaqMan
 PCR
assays that allow for a higher level of standardization and
the deﬁnition of cut-offs for methylation [127]. However,
such cut-offs are just technically substantiated to date, and
there is a need to validate cut-off points prospectively to
establish clinically relevant methylation thresholds.
Another DNA-based methods is methylation-speciﬁc
pyrosequencing [87], which certainly is one of the most
sensitive methods to quantitatively detect even low meth-
ylation signals. The COBRA (combined bisulﬁte restriction
Table 2 Overview of the most commonly used methods for the assessment of molecular markers in gliomas
Method Required material Read out Advantages/disadvantages
MGMT promoter methylation testing
Methylation-speciﬁc PCR analysis Fresh frozen or FFPE
tumor tissue
Gel-based (qualitative) or
quantitative as qPCR
Sensitive/difﬁcult to standardize
Combined bisulﬁte restriction
analysis (COBRA)
Fresh frozen or FFPE
tumor tissue
Gel-based, percentage of cut
versus uncut sequence
High speciﬁcity/test depends on
single restriction sites
Methylation-speciﬁc sequencing Fresh frozen or FFPE
tumor tissue
Methylation status at the CpG sites
within the ampliﬁed sequence
Most comprehensive/difﬁcult to
quantify and work intensive
Methylation-speciﬁc pyrosequencing Fresh frozen or FFPE
tumor tissue
Methylation status at single CpG
sites
Quantitative and rapid/only few
CpG sites analyzed, needs
special equipment
Methylation-speciﬁc multiplex
ligation-dependent probe
ampli-ﬁcation (MS-MLPA)
Fresh frozen or FFPE
tumor tissue
Ratio methylated versus
unmethylated alleles, multiple
CpG sites are evaluated
simultaneously
Independent of sodium bisulﬁte
conversion, provides
semiquantitative data
1p/19q deletion testing
(Flourescence) in situ hybridization
((F)ISH)
Fresh frozen or FFPE
tumor tissue
Signal ratio target versus control
clone in individual cells
Best method on archival
specimens/difﬁcult to quantify,
labor-intensive
Loss of heterozygosity (LOH)
analysis
Fresh frozen or FFPE
tumor tissue plus
additional patient
blood sample
Gel-based detection of allelic
imbalance, comparative
evaluation of the same set of
loci in tumor and blood DNA
Better to test for multiple loci
along a chromosomal arm to
differentiate partial from
complete losses/requires blood
sample/allelic imbalance may
not only be caused by allelic
loss but also by allelic gain
Multiplex ligation-dependent probe
ampliﬁcation (MLPA)
Fresh frozen or FFPE
tumor tissue
Ratio target versus reference probe Multiple loci (up to 45) can be
assessed in a single experiment
IDH1 and IDH2 mutation testing
Single-strand conformation
polymorphism analysis
Fresh frozen or FFPE
tumor tissue
Gel-based detection of aberrant
bands (‘‘shifts’’)
Rapid/limited sensitivity and
laborious, needs to be followed
by sequencing
Direct sequencing Fresh frozen or FFPE
tumor tissue
Complete sequence of the
ampliﬁed DNA fragment
Comprehensive/not quantitative,
limited sensitivity in cases with
low tumor cell content
DNA pyrosequencing Fresh frozen or FFPE
tumor tissue
Sequences information on fewer
nucleotides
Quantitative, rapid, sensitive/needs
special equipment
Immunohistochemistry with
IDH1(R132H)- speciﬁc antibody
Fresh frozen or FFPE
tumor tissue
Histology-based, presence or
absence of staining
Easy to perform in a rotine setting,
very sensitive (single cell level)/
misses other IDH1 or IDH2
mutations
BRAF duplication/fusion testing
(Flourescence) in situ hybridization
((F)ISH)
Fresh frozen or FFPE
tumor tissue
Detection of a fusion signal of 2
ﬂuorescently labeled probes
Cell-based method/difﬁcult to
quantify and standardize
RT-PCR assay Fresh frozen or FFPE
tumor tissue
Gel-based dectection of the fusion
gene
Easy to standardize and quantify/
needs RNA
(Pyro)sequencing Fresh frozen or FFPE
tumor tissue
Detection of BRAF point
mutations
Identiﬁes only the rare cases with
activating point mutations
FFPE formalin-ﬁxed parafﬁn-embedded tissue samples
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123analysis) method employs sodium bisulﬁt treatment of
DNA followed by digestion of PCR products with restric-
tion enzymes that differentially cut at methylated versus
unmethylated sites [87]. Finally, methylation-speciﬁc mul-
tiplex ligation-dependent probe ampliﬁcation (MS-MLPA)
has the advantage that it provides semi-quantitative infor-
mation on the percentage of methylated DNA but does not
depend on a prior conversion of DNA by sodium bisulﬁte
[65]. This may be an advantage because the bisulﬁte con-
version step is particularly critical and every single reaction
should be controlled for complete conversion. Otherwise,
unmethylated cytosins that are not adequately converted by
sodium bisulﬁte may be mistaken for methylated cytosins.
A comprehensive discussion of advantages and disad-
vantages of the individual methods to assess MGMT
promoter methylation is beyond the scope of this review
and has been addressed elsewhere [133]. However, it
should be pointed out that the MGMT promoter methyla-
tion pattern is very heterogeneous from tumor to tumor,
and the relevant CpG sites (or combinations of CpG sites)
that need to be methylated to silence transcription and
provide favorable outcome are not yet deﬁned. Therefore,
one has to be aware that the use of distinct primer com-
binations, even when the same method such as MSP is
used, may result in different results, which may cause
uncertainties when the same tumor is tested at different
laboratories. In this respect, establishment of a consensus
test method that assesses experimentally veriﬁed, most
relevant CpG sites for transcriptional regulation, and is
clinically validated in comparative analyses of the various
techniques would be most desirable. In addition, quality
control measures to ensure the sensitivity and speciﬁcity of
the test across different laboratories need to be established.
IDH1 and IDH2 mutations as novel molecular markers
for diffuse glioma
Mutations in the gene encoding the human cytosolic
NADPH-dependent isocitrate dehydrogenase (IDH1), an
enzyme that participates in the citric acid cycle, were
originally identiﬁed in 2008 employing large scale
sequencing analysis of 22 glioblastomas [95]. All muta-
tions were found in the evolutionarily conserved residue
R132 that is located in the substrate-binding site of IDH1.
The mutations were detected preferentially in glioblasto-
mas of young patients and in secondary glioblastomas [95].
Soon after, multiple studies corroborated these ﬁndings and
additionally revealed that somatic IDH1 mutations are
present in the vast majority of low-grade diffuse (WHO
grade II) and anaplastic (WHO grade III) astrocytic, oli-
godendroglial, and mixed oligodendroglial neoplasms [2,
90, 137]. In a small subset of WHO grade II and III, diffuse
gliomas and secondary glioblastomas that lack IDH1
mutations, the gene of the mitochondrial isoform IDH2 was
found to harbor mutations affecting the analogous amino
acid (R172) [137]. In contrast, IDH1 or IDH2 mutations are
rare in primary glioblastomas and restricted to only indi-
vidual cases of other primary brain tumors [2, 90, 137].
Already the original paper of Parsons et al. [95] recog-
nized that IDH1 mutations were associated with prolonged
overall survival in glioblastoma patients. Subsequent
studies analyzing the whole spectrum of diffuse gliomas
underscored the association between IDH1 mutation and
better outcome, multivariate analyses often revealing IDH1
mutation as a strong and independent favorable prognostic
marker [30, 108, 123, 132, 135]. So far, there is no evi-
dence that the type of IDH1 mutation (R132H vs. non-
R132H) affects patient survival [41]. In contrast to the
strong prognostic signiﬁcance, several studies reported a
lack of predictive signiﬁcance of IDH1 mutations in glio-
mas for response to (chemo)therapy [30, 123].
At the genetic level, the presence of IDH1 mutations in
diffuse gliomas is strongly correlated with TP53 mutation
or 1p/19q deletions [58, 123, 129]. Analysis of multiple
glioma biopsies from the same patient revealed that IDH1
mutations do not occur after the acquisition of either a
TP53 mutation or loss of 1p/19q [129]. In another study, all
128 gliomas with a complete co-deletion of 1p/19q har-
bored an IDH1 or IDH2 mutation [77]. These mutations
thus seem to represent a very early event, affecting a
common glial precursor cell, and may in fact form a pre-
requisite for the t(1;19) translocation leading to 1p/19q co-
deletion and oligodendroglial tumor development. The
presence of IDH1 mutations in gliomas was also reported
to be tightly associated with MGMT promoter methylation
and inversely correlated with the loss of chromosome 10
and EGFR ampliﬁcation [108, 123]. This latter ﬁnding
further underscores the notion that primary and secondary
glioblastomas are genetically distinct entities, despite their
histological similarities [129].
In up to 90% of the diffuse gliomas with mutated IDH1,
the mutation is of the R132H (G395A) type [2, 90, 95,
137]. One study of more than 1,000 diffuse WHO grade II
and III gliomas showed that R132C IDH1 mutations are
associated with astrocytic neoplasms, while IDH2 muta-
tions predominantly occur in oligodendroglial tumors [46].
Another study revealed that non-R132H IDH1 mutations
are rare in classic oligodendrogliomas with 1p/19q loss and
occur at signiﬁcantly higher frequency in other grade II and
III gliomas, including those with TP53 mutations [41].
Interestingly, all ﬁve examined astrocytomas of patients
with Li-Fraumeni syndrome carried R132C IDH1 muta-
tions, indicating that glial/glioma precursor cells with a
germline TP53 mutation carry an increased risk to acquire
such a non-R132H mutation [130].
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of (anaplastic) gangliogliomas [56, 116], supratentorial
primitive neuroectodermal tumors [2] and in gliomatosis
cerebri [112]. IDH mutations are rare or absent in other
glial tumors, such as pilocytic astrocytomas [75, 129] and
ependymomas [129]. Importantly, the vast majority of
high-grade (WHO grade III and IV) gliomas in the pedi-
atric age group lacks IDH1 mutation as well, corroborating
the notion that these pediatric neoplasms are fundamentally
different from their adult counterparts [1, 2, 96]. IDH1
mutations are reported to occur in some non-central ner-
vous system tumors, e.g., a subset of acute myeloid
leukemias with a normal karyotype [23, 103], and occa-
sionally in prostate cancer, B-ALL [23], and
paraganglioma [37]. In the vast majority of non-glial
tumors, however, such mutations are absent [8].
Under physiological conditions, IDH1 and IDH2 are
involved in multiple metabolic processes, such as lipid
synthesis, cellular defense against oxidative stress, oxida-
tive respiration, and signal transduction. There are different
hypotheses on the role of IDH1 and IDH2 mutations in
gliomagenesis, including an effect on the stabilization of
hypoxia inducible factor 1 (HIF-1), upregulation of (other)
genes involved in angiogenesis, glucose transport and
glycolysis, and inhibition of developmental apoptosis [5,
103, 141]. However, recent studies suggest that the het-
erozygous IDH1 and IDH2 mutations in gliomas do not just
result in a loss of function, that is a reduced ability to
catalyze conversion of isocitrate to a-ketoglutarate [137],
but also confer an enzymatic gain of function, in particular
the ability to catalyze the NADPH-dependent reduction of
a-ketoglutarate to 2-hydroxyglutarate (2HG). Indeed, gli-
omas harboring IDH1 mutations demonstrate markedly
elevated levels of 2HG, and this ‘onco-metabolite’ may
contribute to the oncogenesis of gliomas [26]. Similarly,
IDH1 and IDH2 mutations dramatically increase 2HG in
acute myeloid leukemia [43, 128]. Because of the speci-
ﬁcity of the IDH1 and IDH2 mutations in gliomas and of
their metabolic effects, there is hope that these aberrations
provide new avenues for anti-cancer therapies [36]. How-
ever, further study of the (exact effect of) IDH1 and IDH2
mutations is needed to seize this opportunity.
VariousmethodsareappliedforthedetectionofIDH1and/
or IDH2 mutations in clinical glioma specimens (Table 2),
includingsingle-strandconformationpolymorphismanalysis,
direct sequencing [71, 77, 96], PCR-restriction fragment
length polymorphism-based assays [14, 56, 86], DNA py-
rosequencing and real-time PCR with post-PCR ﬂuorescence
meltingcurveanalysisassays[46,55].Especially,theselatter
assays allow for rapid, inexpensive, and sensitive analysis of
IDH1 and IDH2 mutations in routinely processed (i.e. for-
malin-ﬁxed, parafﬁn-embedded) tumor tissue, even in
samples with a low tumor cell content [14, 35, 55]. Only
recently, speciﬁc, and robust monoclonal antibodies were
established that can be used for immunohistochemical anal-
ysis of gliomas bearing the IDH1 R132H mutation [19, 72].
Testing for mutations in IDH1 or IDH2 can now easily and
effectively be performed in a clinical setting and thereby
enhance the diagnostic accuracy, especially, in cases where
traditional methods are insufﬁcient to reach a deﬁnitive
diagnosis. For example, IDH1 and IDH2 mutation analysis
might be helpful in case of a differential diagnosis of diffuse
gliomaversus pilocyticastrocytomaorependymoma,andfor
discrimination between primary and secondary glioblastoma
[56, 75]. Using immunohistochemistry with the anti-
IDH1R132H antibody, even individual cells of gliomas with
the IDH1 R132H mutation (e.g. in the periphery of diffuse
inﬁltrative gliomas) can be detected and differentiated from
non-neoplastic glial cells [19]. Of note, lack of staining with
this antibody does not rule out the presence of an IDH1
mutation (about 10% of the IDH1 mutated gliomas carry a
non-R132H mutation) nor of an IDH2 mutation. Given the
diagnostic and prognostic importance as well as the robust-
nessandrelativeeaseofIDH1andIDH2mutationtesting,itis
very likely that determination of these mutations will soon
become a part of the routine diagnostic assessment of glio-
mas. Furthermore, it needs to be investigated to which extent
the IDH1 and IDH2 status may inﬂuence the classiﬁcation
and subsequent treatment of diffuse gliomas. For example,
one may address interesting questions like (1) should IDH1
and IDH2 wild-type anaplastic gliomas be biologically con-
sidered as glioblastomas that consequently would require
more aggressive treatment when compared with IDH1 or
IDH2 mutant anaplastic gliomas, or (2) should the rare,
prognostically favorable IDH1 mutant primary glioblastoma
be regarded as a separate entity distinct from the ‘‘ordinary’’
IDH1 wild-type primary glioblastoma.
Role of testing for EGF receptor aberrations in gliomas
The epidermal growth factor receptor gene (EGFR) at 7p12
is the most frequently ampliﬁed and overexpressed gene in
primary glioblastomas, affecting approximately 40% of
these tumors [81, 138]. EGFR rearrangements are also fre-
quent, the most common variant being EGFRvIII consisting
of an 801-bp in-frame deletion of exons 2–7 that results in a
constitutively activated truncated receptor protein lacking
theligand-bindingdomain[118].EGFRvIIIrepresentsabout
half of the rearrangements and is identiﬁed in 20–30% of
unselectedprimaryglioblastomasand50–60%oftheEGFR-
ampliﬁed glioblastomas [38]. Identiﬁcation of EGFR
ampliﬁcation and rearrangements, such as EGFRvIII, are
highly indicative for high-grade malignancy and, therefore,
may provide diagnostic as well as prognostic information
[64,81]. In fact, detection of EGFR ampliﬁcation/EGFRvIII
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these tumors are more malignant than indicated by their
histopathology and an unfavorable impact on the prognosis
hasbeendescribedforthesepatients[66,67,115].Inprimary
glioblastoma such prognostic association is less obvious
[132] although other studies reported on EGFR/EGFRvIII
aberrations as poor prognostic factor [27, 89, 97, 113].
DetectionofEGFRaberrationsalsomayberelevantfrom
a therapeutic point of view as inhibition of the EGFR
pathway bears the potential of restoring apoptosis, thereby
increasing the sensitivity to adjuvant therapies. Increased
EGFRvIII signaling was indeed associated with a generally
poor response to radiation and chemotherapy [4, 20, 134].
However, a beneﬁt resulting from the combined treatment
by EGFR inhibition with standard therapies (temozolomide
and radiation therapy) is disputed and as yet the clinical
beneﬁt of the use of EGFR inhibitors in glioblastomas has
been rather disappointing, that is progression-free survival
was not prolonged and only a small subset of individual
patients responded[45,101].Attemptstoidentifyadditional
biomarkers predictive of response to EGFR-related thera-
pies suggested that tumors with EGFRvIII and intact PTEN
[85] or with EGFR ampliﬁcation (but not EGFRvIII) and
low levels of phosphorylated AKT [44] were more likely to
respond to the small molecule tyrosine kinase inhibitors
erlotinib or geﬁtinib. The EGFRvIII mutant, as not being
present in non-neoplastic tissues, also may serve as an
attractive target for immunotherapy [79, 107]. Recent
studies reported that the anti-EGFRvIII peptide vaccine
CDX-110 increased progression-free and overall survival in
EGFRvIII-positive glioblastoma patients when added to
radiochemotherapy [49–51]. Unfortunately, although an
antibody speciﬁcally recognizing EGFRvIII has been
developed for immunohistochemical application, existing
patentscurrentlyprohibittheuseofthisantibodyforclinical
purposes [136, 140]. EGFRvIII analysis alternatively can be
performed by reverse transcription-PCR analysis using
primers located in exons 1 and 9 [79]. Furthermore, MLPA
analysis allows for the detection of EGFR rearrangements
by the simultaneous and semi-quantitative copy number
analysis of multiple small DNA fragments encompassing
different EGFR exons [64, 111], with available assays
detecting EGFRvIII and different other types of rearrange-
ments and being applicable to routinely processed formalin-
ﬁxed and parafﬁn-embedded tissue samples [64].
Special aspects of pediatric gliomas
Aberrant activation of the BRAF proto-oncogene at 7q34,
most commonly by gene duplication and fusion or less fre-
quently by point mutation, has only recently been identiﬁed
as the characteristic genetic aberration in pilocytic
astrocytomas. BRAF gene alterations are detectable in
60–80% of pilocytic astrocytomas, but are infrequent in
diffuselyinﬁltratingastrocyticgliomas[3,69,70,98].Thus,
testing for BRAF gene alterations might be helpful in the
sometimes difﬁcult differential diagnosis between pilocytic
astrocytomas and low-grade diffuse astrocytomas [75].
Detection of the BRAF–KIAA1549 fusion gene can be either
accomplished by FISH analysis or specialized RT-PCR
assays [69, 75] (Table 2). As mentioned above, low-grade
diffuse astrocytoma—in contrast to pilocyticastrocytoma—
would contain frequent mutations in the IDH1 gene and as
such testing for both markers in combination could ﬁnally
turn the scales for one of the two entities. However, IDH1
and IDH2 mutations are generally rare in pediatric astro-
cytomas, including the diffusely inﬁltrating tumors [2, 137],
which implies that the signiﬁcance of diagnostic testing for
these mutations may be lower in pediatric glioma patients.
The frequent BRAF alterations in pilocytic astrocytomas
may have additional clinical implications as a novel thera-
peutic target. Tumors with BRAF duplication or activating
mutation show aberrant signaling via the BRAF pathway. In
vitro studies revealed that both the stable silencing of BRAF
through shRNA lentiviral transduction and pharmacological
inhibition of MEK1/2, the immediate downstream phos-
phorylation target of BRAF, blocked proliferation and
arrested growth of cultured glioma cells [98]. Thus, phar-
macological inhibition of the MAPK pathway may serve as
a potential treatment option in pediatric astrocytoma
patients, as exempliﬁed in a recent case report [106].
Ependymomas also occur relatively frequently in the
pediatric age group. Histological grading of ependymomas
is difﬁcult and there appears to be a less-stringent associ-
ation between tumor grade and prognosis in ependymoma
when compared with astrocytoma patients. However,
recent data suggest that in addition to age at diagnosis, gain
of 1q and homozygous CDKN2A deletion are independent
indicators of unfavorable prognosis, whereas gains of
chromosomes 9, 15q, and 18 and loss of chromosome 6 are
associated with excellent survival for pediatric and adult
patients with intracranial ependymomas [76]. Based on
these ﬁndings, the authors developed a molecular staging
system comprising three genetic risk groups. Thus, the
analysis of genetic markers in addition to established
clinical and histopathologic variables may signiﬁcantly
improve outcome prediction of ependymoma patients and
help to stratify patients into distinct risk groups.
Identiﬁcation of novel biomarkers by genome-wide
proﬁling approaches in gliomas
There are two main trends in glioma research that have
already yielded and probably will yield further molecular
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ﬁling techniques and, mainly driven by the need to work
cost-effectively and to increase sample numbers, the for-
mation of large research networks, such as The Cancer
Genome Atlas Research Network (TCGA) or, more
recently, the International Cancer Genome Consortium
(ICGC) [60].
The success of large scale proﬁling approaches is
exempliﬁed by the ﬁrst detection of IDH1 mutations in a
study that sequenced 20,661 genes in 22 human glioblas-
toma samples [95]. In addition, this study conﬁrmed a set
of glioblastoma candidate genes that mainly functioned
within the p53, pRb1, and Pi3k/Pten signaling pathways
[95]. A publication that was launched contemporaneously
by the TCGA consortium on the integrative analysis of
DNA copy number, gene expression, and DNA methyla-
tion proﬁling in 206 human glioblastomas similarly
reported that the most important pathways that are aberrant
in gliomas are the pRb1/Cdk4/cyclin D/Cdkn2A/B path-
way, the p53 pathway, and the receptor tyrosin kinase/Ras/
Pi3k pathway [18]. Each of these pathways was conﬁrmed
to be disrupted in more than three quarters of glioblasto-
mas, meaning that in most tumors two or all three of these
pathways were involved. Sequencing of glioblastomas for
mutations in 601 selected genes additionally revealed three
previously unrecognized mutations that occurred with
signiﬁcant frequency, namely NF1 gene mutations in 14%,
ERBB2 gene mutations in 8% and PIK3R1 mutations in
nearly 10% of glioblastomas [18]. These novel ﬁndings
may well have impact on future treatment strategies. As an
example, PIK3R1 encodes the regulatory protein p85a
subunit of Pi3k and the response to Pi3k inhibitors may
depend on whether the tumors bear mutations in this spe-
ciﬁc gene or not.
Except for the identiﬁcation of novel individual gene
alterations, the signatures produced by high-throughput
proﬁling techniques themselves might convey clinically
relevant information. In this regard, it was shown that gene
expression-based classiﬁcation of morphologically ambig-
uous high-grade gliomas correlates better with prognosis
than the histological classiﬁcation [92]. Furthermore,
molecular classiﬁcation of gliomas on the basis of genomic
proﬁles obtained by array-CGH closely parallels histolog-
ical classiﬁcation and is able to distinguish, with few
exceptions, between different astrocytoma grades, as well
as between primary and secondary glioblastomas [105].
Phillips et al. [99] ﬁrst reported on three prognostic sub-
classes of high-grade astrocytomas, namely the proneural
(PN), proliferative (Prolif) and mesenchymal (Mes) tumor
subclasses that resemble distinct stages in neurogenesis.
The proneural tumor signature displayed neuronal lineage
markers and was associated with longer survival, while the
proliferative and mesenchymal tumor signatures were both
linked to shorter survival. Upon recurrence, malignant
gliomas frequently shift toward the mesenchymal subclass.
A recent study from the TCGA consortium reported on a
robust gene expression-based molecular classiﬁcation of
glioblastomas into proneural, neural, classical, and mes-
enchymal subtypes [126]. Furthermore, it was found that
genetic aberrations and expression of EGFR, NF1, and
PDGFRA/IDH1 each deﬁne the classical, mesenchymal,
and proneural subtypes, respectively. Response to aggres-
sive therapy was found to differ by subtype, with the
greatest beneﬁt being observed in the classical subtype and
no beneﬁt in the proneural subtype. Interestingly, promoter
DNA methylation proﬁling in 272 TCGA glioblastomas
revealed that a subset of patients had concerted hyperme-
thylation at a large number of loci, indicating the existence
of a glioma-CpG island methylator phenotype (G-CIMP)
[91]. Further investigations showed that G-CIMP tumors
were more common among low-grade gliomas, displayed a
proneural expression signature, frequently carried IDH1
mutations and were associated with signiﬁcantly longer
survival. Other authors also found a tight association
between the IDH1 mutation status and gene expression
proﬁles, suggesting two major pathomechanisms in diffuse
astrocytic gliomas characterized either by IDH1 mutation
and a proneural expression proﬁle, found mostly in diffuse
and anaplastic astrocytomas as well as secondary glio-
blastomas, or by lack of IDH1 mutation and a
mesenchymal/proliferative expression proﬁle [120]. In
addition, IDH1 mutant glioblastomas have been reported to
be frequently accompanied by telomerase-independent
alternative lengthening of telomeres (ALTs), suggesting
that such ALT ? tumors belong to the less aggressive,
‘proneural’ glioblastomas [83].
Although these novel glioma signatures currently incur a
lot of attention, their routine assessment by means of large-
scale mRNA expression proﬁling is not suitable due to the
limited availability and high costs of this approach. How-
ever, a recent study reported that immunhistochemical
expression analysis of a nine gene signature, which is
applicable to routinely processed tissue samples, may be
sufﬁcient to predict glioblastoma outcome [25]. Never-
theless, it remains to be proven that any of these prognostic
gene signatures yields clinically relevant data beyond the
information provided by the analysis of IDH1 mutation,
MGMT promoter methylation and 1p/19q deletion.
A different approach by which large-scale proﬁling
techniques may add in the identiﬁcation of novel glioma
biomarkers is the investigation of deﬁned glioma cell
subpopulations. Malignant gliomas are highly heteroge-
neous and their conventional light-microscopic diagnosis is
based on the recognition of certain histological features,
such as pathological vessel formation, presence/absence of
necroses or an inﬁltrative growth pattern [81]. Bearing in
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lents of deﬁned biologic processes, it appears intriguing to
dissect such tumor cell subpopulations and to assess their
molecular signatures with two closely related goals: ﬁrst, to
foster understanding of the basic processes underlying
glioma biology and secondly, to use these ‘‘subproﬁles’’ to
identify innovative biomarkers that are of relevance for the
tumor’s clinical appraisal as a whole. In this regard, Dong
et al. assessed the molecular proﬁles of perinecrotic pali-
sades in comparison to non-palisading tumor cells distant
from necrosis [29]. In conjunction with preceding studies,
the authors found that the genes most commonly differ-
entially expressed in these palisades conveyed response to
hypoxic environmental conditions [10, 11]. Interestingly, a
set of ﬁve RNAs (POFUT2, PTDSR, PLOD2, ATF5, and
HK2) were not only differentially expressed in three micro-
dissected glioblastomas, but also provided prognostic
information in an independent set of glioblastoma patients.
Thus, it appears feasible to derive tissue biomarkers that
provide ancillary prognostic and predictive information
from the study of deﬁned subpopulations of tumor cells. Of
course, this approach is not restricted to pseudopalisading
tumor cells, but may be extended to other glioma cell
subpopulations, e.g. tumor cells selected for their invasive
or stemness properties [6, 28, 54].
Novel mechanistic insights into molecular alterations
underlying treatment resistance of gliomas
Large-scale proﬁling approaches have also advanced the
understanding of the molecular mechanisms that underlie
treatment resistance in high-grade gliomas. Investigating
gliomas that had recurred after treatment with alkylating
agents, Hunter et al. identiﬁed somatic mutations of the
mismatch repair gene MSH6 in a large-scale sequencing
approach of the functional domains of 518 protein kinases
[57]. These ﬁndings were further evaluated in an inde-
pendent panel of 46 clinically well-documented
glioblastomas [15]. Indeed, in recurrent glioblastomas, the
rate of MSH6 mutations was signiﬁcantly increased adding
further evidence to a potential causal link between MSH6
deﬁciency and treatment resistance.
Interestingly, a subsequent publication reported that
MSH6 mutations arise in glioblastomas during temozolo-
mide therapy and mediate temozolomide resistance [139].
In vitro modeling through exposure of a MSH6 wild-type
glioblastoma line to temozolomide resulted in resistant
clones with one clone showing an MSH6 mutation, namely
Thr(1219)Ile, which had also been noted in two treated
glioblastomas of the TCGA cohort [18]. Moreover,
knockdown of MSH6 in the glioblastoma cell line U251
increased resistance to temozolomide cytotoxicity and
reconstitution restored cytotoxicity in MSH6-null glioma
cells. These ﬁndings indicate that MSH6 mutations and/or
mutations in other DNA mismatch repair genes are selected
in glioblastomas during temozolomide therapy and that
patients who initially responded to a frontline therapy, i.e.,
particularly patients with MGMT-hypermethylated tumors,
may develop treatment resistance by acquiring a hyper-
mutator phenotype involving frequent mutations in DNA
mismatch repair genes. As a perspective, combination of
alkylating chemotherapy with molecular strategies target-
ing DNA mismatch repair-deﬁcient cells may help in
preventing or minimizing treatment resistance of gliomas.
Although undoubtedly representing a relevant novel
discovery, MSH6 mutations may be just the tip of an ice-
berg of molecular changes that are associated with
treatment response. Furthermore, these mutations appear
not be linked to high-level microsatellite instability in
gliomas [82]. Other studies have reported that alteration of
the base excision repair pathway may sensitize glioma cells
to temozolomide treatment and suggested inhibition of
poly(ADP-ribose)polymerase as a promising therapeutic
approach [21, 84, 119]. Furthermore, large-scale hetero-
chromatin reorganization has been observed in glioma cells
following treatment with temozolomide and carmustine,
suggesting that treatment efﬁcacy may implicate a ﬁrst
event characterized by changes in heterochromatin orga-
nization and, conversely, treatment failure may be
associated with the aberrant euchromatinization of novel,
yet to be identiﬁed chemotherapy resistance genes [94].
Another study aiming at identifying molecular proﬁles
speciﬁc of treatment resistance to temozolomide identiﬁed
a ‘‘glioma stem cell’’ or ‘‘self-renewal’’ expression signa-
ture as a predictor of poor survival [89]. This signature
proved an independent prognostic factor also in multivar-
iate analyses adjusted for the MGMT promoter methylation
status and contained HOX genes as well as the putative
glioma stem cell marker prominin-1 (CD133). Thus, in
access to the identiﬁcation of individual candidate genes
like MSH6, large-scale proﬁling approaches might help to
uncover more complex molecular proﬁles associated with
treatment resistance. These proﬁles, although still pre-
liminary, may help in identifying ‘‘pathways of therapy
failure’’ that eventually could be speciﬁcally targeted.
Conclusions and perspectives
Molecular and translational glioma research has signiﬁ-
cantly advanced the understanding of glioma pathogenesis
and identiﬁed a number of diagnostic, prognostic and/or
predictive molecular markers that currently are on their way
into clinical application. In fact, the antibody against the
IDH1 R132H mutation is already used in many
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marker for the differential diagnosis of diffusely inﬁltrating
gliomas versus reactive astrogliosis [25]. Furthermore, both
1p/19q deletion and MGMT promoter methylation are
presently being used to stratify patients into different clin-
ical trials, each testing for the efﬁcacy of different drugs or
administration schemes in comparison to the respective
standard protocol. In case that these studies will proof
successful, it is to be foreseen that molecular assessment of
the relevant markers will have to be implemented into the
routine diagnostic setting outside of clinical trials. Clear
cut-off levels for each molecular assay have to be developed
and appropriate quality measures have to be established to
ensure comparable sensitivity and speciﬁcity of molecular
test results across different laboratories. Histological con-
trol of the tissue specimens used for molecular testing also
is an important issue that requires an experienced neuro-
pathologist to avoid false-negative test results due to
inappropriate samples with too low tumor cell content.
In the near future, novel insights into the pathogenesis of
gliomas are to be expected from ongoing, large-scale col-
laborative proﬁling studies addressing the complexity of
genetic, epigenetic, transcriptomic, and miRNA changes by
high-resolution array-based techniques or deep sequencing
approaches. It appears very likely that these studies will
uncover novel molecular markers that may further reﬁne the
diagnostic assessment of gliomas. However, the future role
of molecular diagnostics in neurooncology, in particular
concerning the value of predictive markers will also depend
on the development and availability of novel therapeutic
alternatives to allow for more sophisticated patient-tailored
treatment choices based on molecular proﬁles.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Antonelli M, Buttarelli FR, Arcella A, Nobusawa S, Donofrio V,
Oghaki H and Giangaspero F (2010) Prognostic signiﬁcance of
histological grading, p53 status, YKL-40 expression, and IDH1
mutations in pediatric high-grade gliomas. J Neurooncol [Epub
ahead of print]
2. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von
Deimling A (2008) Analysis of the IDH1 codon 132 mutation in
brain tumors. Acta Neuropathol 116:597–602
3. Bar EE, Lin A, Tihan T, Burger PC, Eberhart CG (2008) Fre-
quent gains at chromosome 7q34 involving BRAF in pilocytic
astrocytoma. J Neuropathol Exp Neurol 67:878–887
4. Barker FG 2nd, Simmons ML, Chang SM, Prados MD, Larson
DA, Sneed PK, Wara WM, Berger MS, Chen P, Israel MA,
Aldape KD (2001) EGFR overexpression and radiation response
in glioblastoma multiforme. Int J Radiat Oncol Biol Phys
51:410–418
5. Bayley JP, Devilee P (2010) Warburg tumours and the mecha-
nisms of mitochondrial tumour suppressor genes. Barking up the
right tree? Curr Opin Genet Dev 20:324–329
6. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J,
Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP (2007)
CD133(?) and CD133(-) glioblastoma-derived cancer stem
cells show differential growth characteristics and molecular
proﬁles. Cancer Res 67:4010–4015
7. Belanich M, Pastor M, Randall T, Guerra D, Kibitel J, Alas L, Li
B, Citron M, Wasserman P, White A, Eyre H, Jaeckle K,
Schulman S, Rector D, Prados M, Coons S, Shapiro W, Yarosh
D (1996) Retrospective study of the correlation between the
DNA repair protein alkyltransferase and survival of brain tumor
patients treated with carmustine. Cancer Res 56:783–788
8. Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Van-
dertop WP, Frattini M, Molinari F, Knowles M, Cerrato A,
Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S,
Marchetti A, Bardelli A (2009) IDH1 mutations at residue
p.R132 (IDH1(R132)) occur frequently in high-grade gliomas
but not in other solid tumors. Hum Mutat 30:7–11
9. Brandes AA, Nicolardi L, Tosoni A, Gardiman M, Iuzzolino P,
Ghimenton C, Reni M, Rotilio A, Sotti G, Ermani M (2006)
Survival following adjuvant PCV or temozolomide for ana-
plastic astrocytoma. Neuro Oncol 8:253–260
10. Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C,
Hammond EH, Devi SN, Kaur B, Van Meir EG (2004) Pseud-
opalisades in glioblastoma are hypoxic, express extracellular
matrix proteases, and are formed by an actively migrating cell
population. Cancer Res 64:920–927
11. Brat DJ, Van Meir EG (2004) Vaso-occlusive and prothrombotic
mechanisms associated with tumor hypoxia, necrosis, and
accelerated growth in glioblastoma. Lab Invest 84:397–405
12. Brokinkel B, Fischer BR, Peetz-Dienhart S, Ebel H, Sepehrnia
A, Rama B, Albert FK, Stummer W, Paulus W and Hasselblatt
M (2010) MGMT promoter methylation status in anaplastic
meningiomas. J Neurooncol [Epub ahead of print]
13. Buccoliero AM, Castiglione F, Rossi Degl’Innocenti D, Pag-
lierani M, Maio V, Gheri CF, Garbini F, Moncini D, Taddei A,
Sardi I, Sanzo M, Giordano F, Mussa F, Genitori L, Taddei GL
(2008) O6-Methylguanine-DNA-methyltransferase in recurring
anaplastic ependymomas: PCR and immunohistochemistry.
J Chemother 20:263–268
14. Bujko M, Kober P, Matyja E, Nauman P, Dyttus-Cebulok K,
Czeremszynska B, Bonicki W, Siedlecki JA (2010) Prognostic
value of IDH1 mutations identiﬁed with PCR-RFLP assay in
glioblastoma patients. Mol Diagn Ther 14:163–169
15. Cahill DP, Levine KK, Betensky RA, Codd PJ, Romany CA,
Reavie LB, Batchelor TT, Futreal PA, Stratton MR, Curry WT,
Iafrate AJ, Louis DN (2007) Loss of the mismatch repair protein
MSH6 in human glioblastomas is associated with tumor pro-
gression during temozolomide treatment. Clin Cancer Res
13:2038–2045
16. Cairncross G, Berkey B, Shaw E, Jenkins R, Scheithauer B,
Brachman D, Buckner J, Fink K, Souhami L, Laperierre N, Mehta
M, Curran W (2006) Phase III trial of chemotherapy plus radio-
therapy compared with radiotherapy alone for pure and mixed
anaplastic oligodendroglioma: Intergroup Radiation Therapy
Oncology Group Trial 9402. J Clin Oncol 24:2707–2714
17. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM,
Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y,
Ramsay DA, Louis DN (1998) Speciﬁc genetic predictors of
chemotherapeutic response and survival in patients with ana-
plastic oligodendrogliomas. J Natl Cancer Inst 90:1473–1479
18. Cancer Genome Atlas Research Network (2008) Comprehensive
genomic characterization deﬁnes human glioblastoma genes and
core pathways. Nature 455:1061–1068
Acta Neuropathol (2010) 120:567–584 579
12319. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D,
Ackermann U, Tessmer C, Korshunov A, Zentgraf H, Hartmann
C, von Deimling A (2010) Characterization of R132H mutation-
speciﬁc IDH1 antibody binding in brain tumors. Brain Pathol
20:245–254
20. Chakravarti A, Chakladar A, Delaney MA, Latham DE, Loefﬂer
JS (2002) The epidermal growth factor receptor pathway
mediates resistance to sequential administration of radiation and
chemotherapy in primary human glioblastoma cells in a RAS-
dependent manner. Cancer Res 62:4307–4315
21. Cheng CL, Johnson SP, Keir ST, Quinn JA, Ali-Osman F, Szabo
C, Li H, Salzman AL, Dolan ME, Modrich P, Bigner DD,
Friedman HS (2005) Poly(ADP-ribose) polymerase-1 inhibition
reverses temozolomide resistance in a DNA mismatch repair-
deﬁcient malignant glioma xenograft. Mol Cancer Ther
4:1364–1368
22. Chinot OL, Barrie M, Fuentes S, Eudes N, Lancelot S, Metellus
P, Muracciole X, Braguer D, Ouaﬁk L, Martin PM, Dufour H,
Figarella-Branger D (2007) Correlation between O6-methyl-
guanine-DNA methyltransferase and survival in inoperable
newly diagnosed glioblastoma patients treated with neoadjuvant
temozolomide. J Clin Oncol 25:1470–1475
23. Chou WC, Hou HA, Chen CY, Tang JL, Yao M, Tsay W, Ko
BS, Wu SJ, Huang SY, Hsu SC, Chen YC, Huang YN, Chang
YC, Lee FY, Liu MC, Liu CW, Tseng MH, Huang CF, Tien HF
(2010) Distinct clinical and biologic characteristics in adult
acute myeloid leukemia bearing the isocitrate dehydrogenase 1
mutation. Blood 115:2749–2754
24. Claes A, Idema AJ, Wesseling P (2007) Diffuse glioma growth:
a guerilla war. Acta Neuropathol 114:443–458
25. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL,
Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert
MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, Bhat
K, Feuerstein BG, Jenkins RB, Aldape K (2010) A multigene
predictor of outcome in glioblastoma. Neuro Oncol 12:49–57
26. Dang L, White DW, Gross S, Bennett BD, Bittinger MA,
Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks
KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD,
Cantley LC, Thompson CB, Vander Heiden MG, Su SM (2009)
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.
Nature 462:739–744
27. Dehais C, Laigle-Donadey F, Marie Y, Kujas M, Lejeune J,
Benouaich-Amiel A, Pedretti M, Polivka M, Xuan KH, Thillet J,
Delattre JY, Sanson M (2006) Prognostic stratiﬁcation of
patients with anaplastic gliomas according to genetic proﬁle.
Cancer 107:1891–1897
28. Delic S, Schmidt N, Lottmann N, Stefanski A, Stuhler K, Rei-
fenberger G, Riemenschneider MJ (2009) In vivo and in vitro
selection of inﬁltrating glioma cells: a comprehensive, multi-
dimensional molecular analysis of the invasive phenotype of
human glioblastomas. Acta Neuropathol 118:437–437 (Meeting
Abstract)
29. Dong S, Nutt CL, Betensky RA, Stemmer-Rachamimov AO,
Denko NC, Ligon KL, Rowitch DH, Louis DN (2005) Histol-
ogy-based expression proﬁling yields novel prognostic markers
in human glioblastoma. J Neuropathol Exp Neurol 64:948–955
30. Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I,
Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ,
Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens
WN, van den Bent MJ (2009) IDH1 mutations in low-grade
astrocytomas predict survival but not response to temozolomide.
Neurology 73:1792–1795
31. Ebinger M, Senf L, Wachowski O, Scheurlen W (2004) Pro-
moter methylation pattern of caspase-8, P16INK4A, MGMT,
TIMP-3, and E-cadherin in medulloblastoma. Pathol Oncol Res
10:17–21
32. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN,
Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000)
Inactivation of the DNA-repair gene MGMT and the clinical
response of gliomas to alkylating agents. N Engl J Med
343:1350–1354
33. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blas-
chke B, Schlegel U, Schramm J, Wiestler OD, Reifenberger G
(2004) Oligodendroglial tumors: reﬁnement of candidate regions
on chromosome arm 1p and correlation of 1p/19q status with
survival. Brain Pathol 14:121–130
34. Felsberg J, Rapp M, Loeser S, Fimmers R, Stummer W,
Goeppert M, Steiger HJ, Friedensdorf B, Reifenberger G, Sabel
MC (2009) Prognostic signiﬁcance of molecular markers and
extent of resection in primary glioblastoma patients. Clin Cancer
Res 15:6683–6693
35. Felsberg J, Wolter M, Seul H, Friedensdorf B, Goppert M, Sabel
MC, Reifenberger G (2010) Rapid and sensitive assessment of
the IDH1 and IDH2 mutation status in cerebral gliomas based on
DNA pyrosequencing. Acta Neuropathol 119:501–507
36. Fu Y, Huang R, Du J, Yang R, An N, Liang A (2010) Glioma-
derived mutations in IDH: from mechanism to potential therapy.
Biochem Biophys Res Commun 397:127–130
37. Gaal J, Burnichon N, Korpershoek E, Roncelin I, Bertherat J,
Plouin PF, de Krijger RR, Gimenez-Roqueplo AP, Dinjens WN
(2010) Isocitrate dehydrogenase mutations are rare in pheo-
chromocytomas and paragangliomas. J Clin Endocrinol Metab
95:1274–1278
38. Gan HK, Kaye AH, Luwor RB (2009) The EGFRvIII variant in
glioblastoma multiforme. J Clin Neurosci 16:748–754
39. Gerson SL (2004) MGMT: its role in cancer aetiology and
cancer therapeutics. Nat Rev Cancer 4:296–307
40. Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB,
Mehta M, Curran WJ, Aldape K (2008) Anaplastic oligoden-
droglial tumors: reﬁning the correlation among histopathology,
1p 19q deletion and clinical outcome in Intergroup Radiation
Therapy Oncology Group Trial 9402. Brain Pathol 18:360–369
41. Gravendeel LA, Kloosterhof NK, Bralten LB, van Marion R,
Dubbink HJ, Dinjens W, Bleeker FE, Hoogenraad CC, Michiels
E, Kros JM, van den Bent M, Smitt PA, French PJ (2010)
Segregation of non-p.R132H mutations in IDH1 in distinct
molecular subtypes of glioma. Hum Mutat 31:E1186–E1199
42. Grifﬁn CA, Burger P, Morsberger L, Yonescu R, Swierczynski
S, Weingart JD, Murphy KM (2006) Identiﬁcation of
der(1;19)(q10;p10) in ﬁve oligodendrogliomas suggests mech-
anism of concurrent 1p and 19q loss. J Neuropathol Exp Neurol
65:988–994
43. Gross S, Cairns RA, Minden MD, Driggers EM, Bittinger MA,
Jang HG, Sasaki M, Jin S, Schenkein DP, Su SM, Dang L,
Fantin VR, Mak TW (2010) Cancer-associated metabolite 2-
hydroxyglutarate accumulates in acute myelogenous leukemia
with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med
207:339–344
44. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma
N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M,
Berger MS, Stokoe D (2005) Epidermal growth factor receptor,
protein kinase B/Akt, and glioma response to erlotinib. J Natl
Cancer Inst 97:880–887
45. Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz
CR (2006) Epidermal growth factor receptor inhibition for the
treatment of glioblastoma multiforme and other malignant brain
tumours. Cancer Treat Rev 32:74–89
46. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians
A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M,
Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P,
Reifenberger G, von Deimling A (2009) Type and frequency of
IDH1 and IDH2 mutations are related to astrocytic and
580 Acta Neuropathol (2010) 120:567–584
123oligodendroglial differentiation and age: a study of 1,010 diffuse
gliomas. Acta Neuropathol 118:469–474
47. Hatanpaa KJ, Burger PC, Eshleman JR, Murphy KM, Berg KD
(2003) Molecular diagnosis of oligodendroglioma in parafﬁn
sections. Lab Invest 83:419–428
48. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N,
Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L,
Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer
RC, Stupp R (2005) MGMT gene silencing and beneﬁt from
temozolomide in glioblastoma. N Engl J Med 352:997–1003
49. Heimberger AB, Crotty LE, Archer GE, Hess KR, Wikstrand
CJ, Friedman AH, Friedman HS, Bigner DD, Sampson JH
(2003) Epidermal growth factor receptor VIII peptide vaccina-
tion is efﬁcacious against established intracerebral tumors. Clin
Cancer Res 9:4247–4254
50. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert
M, Sawaya R, Aldape K (2005) Prognostic effect of epidermal
growth factor receptor and EGFRvIII in glioblastoma multi-
forme patients. Clin Cancer Res 11:1462–1466
51. Heimberger AB, Sampson JH (2009) The PEPvIII-KLH (CDX-
110) vaccine in glioblastoma multiforme patients. Expert Opin
Biol Ther 9:1087–1098
52. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB
(1996) Methylation-speciﬁc PCR: a novel PCR assay for
methylation status of CpG islands. Proc Natl Acad Sci USA
93:9821–9826
53. Herrlinger U, Rieger J, Koch D, Loeser S, Blaschke B, Kort-
mann RD, Steinbach JP, Hundsberger T, Wick W, Meyermann
R, Tan TC, Sommer C, Bamberg M, Reifenberger G, Weller M
(2006) Phase II trial of lomustine plus temozolomide chemo-
therapy in addition to radiotherapy in newly diagnosed
glioblastoma: UKT-03. J Clin Oncol 24:4412–4417
54. Hoelzinger DB, Mariani L, Weis J, Woyke T, Berens TJ,
McDonough WS, Sloan A, Coons SW, Berens ME (2005) Gene
expression proﬁle of glioblastoma multiforme invasive pheno-
type points to new therapeutic targets. Neoplasia 7:7–16
55. Horbinski C, Kelly L, Nikiforov YE, Durso MB, Nikiforova MN
(2010) Detection of IDH1 and IDH2 mutations by ﬂuorescence
melting curve analysis as a diagnostic tool for brain biopsies.
J Mol Diagn 12:487–492
56. Horbinski C, Koﬂer J, Kelly LM, Murdoch GH, Nikiforova MN
(2009) Diagnostic use of IDH1/2 mutation analysis in routine
clinical testing of formalin-ﬁxed, parafﬁn-embedded glioma
tissues. J Neuropathol Exp Neurol 68:1319–1325
57. Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J,
Greenman C, Edkins S, Bignell G, Davies H, O’Meara S, Parker
A, Avis T, Barthorpe S, Brackenbury L, Buck G, Butler A,
Clements J, Cole J, Dicks E, Forbes S, Gorton M, Gray K,
Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D,
Kosmidou V, Laman R, Lugg R, Menzies A, Perry J, Petty R,
Raine K, Richardson D, Shepherd R, Small A, Solomon H, Tofts
C, Varian J, West S, Widaa S, Yates A, Easton DF, Riggins G,
Roy JE, Levine KK, Mueller W, Batchelor TT, Louis DN,
Stratton MR, Futreal PA, Wooster R (2006) A hypermutation
phenotype and somatic MSH6 mutations in recurrent human
malignant gliomas after alkylator chemotherapy. Cancer Res
66:3987–3991
58. Ichimura K, Pearson DM, Kocialkowski S, Backlund LM, Chan
R, Jones DT, Collins VP (2009) IDH1 mutations are present in
the majority of common adult gliomas but rare in primary
glioblastomas. Neuro Oncol 11:341–347
59. Ino Y, Betensky RA, Zlatescu MC, Sasaki H, Macdonald DR,
Stemmer-Rachamimov AO, Ramsay DA, Cairncross JG, Louis
DN (2001) Molecular subtypes of anaplastic oligodendroglioma:
implications for patient management at diagnosis. Clin Cancer
Res 7:839–845
60. International Cancer Genome Consortium (2010) International
network of cancer genome projects. Nature 464:993–998
61. Jaeckle KA, Eyre HJ, Townsend JJ, Schulman S, Knudson HM,
Belanich M, Yarosh DB, Bearman SI, Giroux DJ, Schold SC
(1998) Correlation of tumor O6 methylguanine-DNA methyl-
transferase levels with survival of malignant astrocytoma
patients treated with bis-chloroethylnitrosourea: a Southwest
Oncology Group study. J Clin Oncol 16:3310–3315
62. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM,
Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG,
Buckner JC (2006) A t(1;19)(q10;p10) mediates the combined
deletions of 1p and 19q and predicts a better prognosis of
patients with oligodendroglioma. Cancer Res 66:9852–9861
63. Jeuken J, Cornelissen S, Boots-Sprenger S, Gijsen S, Wesseling
P (2006) Multiplex ligation-dependent probe ampliﬁcation: a
diagnostic tool for simultaneous identiﬁcation of different
genetic markers in glial tumors. J Mol Diagn 8:433–443
64. Jeuken J, Sijben A, Alenda C, Rijntjes J, Dekkers M, Boots-
Sprenger S, McLendon R, Wesseling P (2009) Robust detection
of EGFR copy number changes and EGFR variant III: technical
aspects and relevance for glioma diagnostics. Brain Pathol
19:661–671
65. Jeuken JW, Cornelissen SJ, Vriezen M, Dekkers MM, Errami A,
Sijben A, Boots-Sprenger SH, Wesseling P (2007) MS-MLPA:
an attractive alternative laboratory assay for robust, reliable, and
semiquantitative detection of MGMT promoter hypermethyla-
tion in gliomas. Lab Invest 87:1055–1065
66. Jeuken JW, Sprenger SH, Boerman RH, von Deimling A,
Teepen HL, van Overbeeke JJ, Wesseling P (2001) Subtyping of
oligo-astrocytic tumours by comparative genomic hybridization.
J Pathol 194:81–87
67. Jeuken JW, Sprenger SH, Wesseling P, Macville MV, von
Deimling A, Teepen HL, van Overbeeke JJ, Boerman RH
(1999) Identiﬁcation of subgroups of high-grade oligodendrog-
lial tumors by comparative genomic hybridization.
J Neuropathol Exp Neurol 58:606–612
68. Jeuken JW, von Deimling A, Wesseling P (2004) Molecular
pathogenesis of oligodendroglial tumors. J Neurooncol
70:161–181
69. Jones DT, Kocialkowski S, Liu L, Pearson DM, Backlund LM,
Ichimura K, Collins VP (2008) Tandem duplication producing a
novel oncogenic BRAF fusion gene deﬁnes the majority of
pilocytic astrocytomas. Cancer Res 68:8673–8677
70. Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K,
Collins VP (2009) Oncogenic RAF1 rearrangement and a novel
BRAF mutation as alternatives to KIAA1549:BRAF fusion in
activating the MAPK pathway in pilocytic astrocytoma. Onco-
gene 28:2119–2123
71. Kang MR, Kim MS, Oh JE, Kim YR, Song SY, Seo SI, Lee JY,
Yoo NJ, Lee SH (2009) Mutational analysis of IDH1 codon 132
in glioblastomas and other common cancers. Int J Cancer
125:353–355
72. Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD
(2009) A monoclonal antibody IMab-1 speciﬁcally recognizes
IDH1R132H, the most common glioma-derived mutation. Bio-
chem Biophys Res Commun 390:547–551
73. Kleihues P, Ohgaki H (1999) Primary and secondary glioblas-
tomas: from concept to clinical diagnosis. Neuro-oncol 1:44–51
74. Koos B, Peetz-Dienhart S, Riesmeier B, Fruhwald MC, Has-
selblatt M (2010) O(6)-methylguanine-DNA methyltransferase
(MGMT) promoter methylation is signiﬁcantly less frequent in
ependymal tumours as compared to malignant astrocytic glio-
mas. Neuropathol Appl Neurobiol 36:356–358
75. Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt
H, Pﬁster S, von Deimling A, Hartmann C (2009) Combined
molecular analysis of BRAF and IDH1 distinguishes pilocytic
Acta Neuropathol (2010) 120:567–584 581
123astrocytoma from diffuse astrocytoma. Acta Neuropathol
118:401–405
76. Korshunov A, Witt H, Hielscher T, Benner A, Remke M, Ry-
zhova M, Milde T, Bender S, Wittmann A, Schottler A, Kulozik
AE, Witt O, von Deimling A, Lichter P, Pﬁster S (2010)
Molecular staging of intracranial ependymoma in children and
adults. J Clin Oncol 28:3182–3190
77. Labussiere M, Idbaih A, Wang XW, Marie Y, Boisselier B,
Falet C, Paris S, Laffaire J, Carpentier C, Criniere E, Ducray F,
El Hallani S, Mokhtari K, Hoang-Xuan K, Delattre JY, Sanson
M (2010) All the 1p19q codeleted gliomas are mutated on IDH1
or IDH2. Neurology 74:1886–1890
78. Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y,
Siegal T (2006) Progressive low-grade oligodendrogliomas:
response to temozolomide and correlation between genetic
proﬁle and O6-methylguanine DNA methyltransferase protein
expression. Cancer 106:1759–1765
79. Li G, Wong AJ (2008) EGF receptor variant III as a target antigen
for tumor immunotherapy. Expert Rev Vaccines 7:977–985
80. Linz U (2010) Commentary on Effects of radiotherapy with
concomitant and adjuvant temozolomide versus radiotherapy
alone on survival in glioblastoma in a randomised phase III
study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol.
2009;10:459-466). Cancer 116:1844–1846
81. Louis DN, Ohgaki H, Wiestler OD, CaveneeWK (eds) (2007)
WHO classiﬁcation of tumours of the central nervous system,
3rd edn. IARC Press, Lyon
82. Maxwell JA, Johnson SP, McLendon RE, Lister DW, Horne KS,
Rasheed A, Quinn JA, Ali-Osman F, Friedman AH, Modrich
PL, Bigner DD, Friedman HS (2008) Mismatch repair deﬁ-
ciency does not mediate clinical resistance to temozolomide in
malignant glioma. Clin Cancer Res 14:4859–4868
83. McDonald KL, McDonnell J, Muntoni A, Henson JD, Hegi ME,
von Deimling A, Wheeler HR, Cook RJ, Biggs MT, Little NS,
Robinson BG, Reddel RR, Royds JA (2010) Presence of alter-
native lengthening of telomeres mechanism in patients with
glioblastoma identiﬁes a less aggressive tumor type with longer
survival. J Neuropathol Exp Neurol 69:729–736
84. McEllin B, Camacho CV, Mukherjee B, Hahm B, Tomimatsu N,
Bachoo RM, Burma S (2010) PTEN loss compromises homol-
ogous recombination repair in astrocytes: implications for
glioblastoma therapy with temozolomide or poly(ADP-ribose)
polymerase inhibitors. Cancer Res 70:5457–5464
85. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S,
Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL,
Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck
TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF,
Sawyers CL, Mischel PS (2005) Molecular determinants of the
response of glioblastomas to EGFR kinase inhibitors. N Engl J
Med 353:2012–2024
86. Meyer J, Pusch S, Balss J, Capper D, Mueller W, Christians A,
Hartmann C, von Deimling A (2010) PCR- and restriction
endonuclease-based detection of IDH1 mutations. Brain Pathol
20:298–300
87. Mikeska T, Bock C, El-Maarri O, Hubner A, Ehrentraut D,
Schramm J, Felsberg J, Kahl P, Buttner R, Pietsch T, Waha A
(2007) Optimization of quantitative MGMT promoter methyla-
tion analysis using pyrosequencing and combined bisulﬁte
restriction analysis. J Mol Diagn 9:368–381
88. Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger
G (2005) Frequent promoter hypermethylation and low expres-
sion of the MGMT gene in oligodendroglial tumors. Int J Cancer
113:379–385
89. Murat A, Migliavacca E, Gorlia T, Lambiv WL, Shay T, Hamou
MF, de Tribolet N, Regli L, Wick W, Kouwenhoven MC,
Hainfellner JA, Heppner FL, Dietrich PY, Zimmer Y,
Cairncross JG, Janzer RC, Domany E, Delorenzi M, Stupp R,
Hegi ME (2008) Stem cell-related ‘‘self-renewal’’ signature and
high epidermal growth factor receptor expression associated
with resistance to concomitant chemoradiotherapy in glioblas-
toma. J Clin Oncol 26:3015–3024
90. Nobusawa S, Watanabe T, Kleihues P, Ohgaki H (2009) IDH1
mutations as molecular signature and predictive factor of sec-
ondary glioblastomas. Clin Cancer Res 15:6002–6007
91. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara
K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP,
Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK,
Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H,
Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird
PW, Aldape K (2010) Identiﬁcation of a CpG island methylator
phenotype that deﬁnes a distinct subgroup of glioma. Cancer
Cell 17:510–522
92. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG,
Ladd C, Pohl U, Hartmann C, McLaughlin ME, Batchelor TT,
Black PM, von Deimling A, Pomeroy SL, Golub TR, Louis DN
(2003) Gene expression-based classiﬁcation of malignant
gliomas correlates better with survival than histological classi-
ﬁcation. Cancer Res 63:1602–1607
93. Ohgaki H, Kleihues P (2007) Genetic pathways to primary and
secondary glioblastoma. Am J Pathol 170:1445–1453
94. Papait R, Magrassi L, Rigamonti D, Cattaneo E (2009) Tem-
ozolomide and carmustine cause large-scale heterochromatin
reorganization in glioma cells. Biochem Biophys Res Commun
379:434–439
95. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P,
Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R,
Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA,
Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL,
Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin
R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu
VE, Kinzler KW (2008) An integrated genomic analysis of
human glioblastoma multiforme. Science 321:1807–1812
96. Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J,
Bax DA, Coyle B, Barrow J, Hargrave D, Lowe J, Gajjar A,
Zhao W, Broniscer A, Ellison DW, Grundy RG, Baker SJ (2010)
Integrated molecular genetic proﬁling of pediatric high-grade
gliomas reveals key differences with the adult disease. J Clin
Oncol 28:3061–3068
97. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman
EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY,
Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG
2nd, Buckner JC, James CD, Aldape K (2007) Epidermal growth
factor receptor variant III status deﬁnes clinically distinct sub-
types of glioblastoma. J Clin Oncol 25:2288–2294
98. Pﬁster S, Janzarik WG, Remke M, Ernst A, Werft W, Becker N,
Toedt G, Wittmann A, Kratz C, Olbrich H, Ahmadi R, Thieme
B, Joos S, Radlwimmer B, Kulozik A, Pietsch T, Herold-Mende
C, Gnekow A, Reifenberger G, Korshunov A, Scheurlen W,
Omran H, Lichter P (2008) BRAF gene duplication constitutes a
mechanism of MAPK pathway activation in low-grade astro-
cytomas. J Clin Invest 118:1739–1749
99. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu
TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM,
Modrusan Z, Feuerstein BG, Aldape K (2006) Molecular sub-
classes of high-grade glioma predict prognosis, delineate a
pattern of disease progression, and resemble stages in neuro-
genesis. Cancer Cell 9:157–173
100. Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ,
Holmes EJ, Zhou T, Finlay JL (2006) O6-methylguanine-DNA
methyltransferase expression strongly correlates with outcome
in childhood malignant gliomas: results from the CCG-945
cohort. J Clin Oncol 24:3431–3437
582 Acta Neuropathol (2010) 120:567–584
123101. Preusser M, Gelpi E, Rottenfusser A, Dieckmann K, Widhalm
G, Dietrich W, Bertalanffy A, Prayer D, Hainfellner JA, Marosi
C (2008) Epithelial growth factor receptor inhibitors for treat-
ment of recurrent or progressive high grade glioma: an
exploratory study. J Neurooncol 89:211–218
102. Reifenberger G, Louis DN (2003) Oligodendroglioma: toward
molecular deﬁnitions in diagnostic neuro-oncology. J Neuropa-
thol Exp Neurol 62:111–126
103. Reitman ZJ, Yan H (2010) Isocitrate dehydrogenase 1 and 2
mutations in cancer: alterations at a crossroads of cellular
metabolism. J Natl Cancer Inst 102:932–941
104. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C,
Sulman EP, Bekele BN, Aldape KD (2010) MGMT promoter
methylation is predictive of response to radiotherapy and
prognostic in the absence of adjuvant alkylating chemotherapy
for glioblastoma. Neuro Oncol 12:116–121
105. Roerig P, Nessling M, Radlwimmer B, Joos S, Wrobel G,
Schwaenen C, Reifenberger G, Lichter P (2005) Molecular
classiﬁcation of human gliomas using matrix-based comparative
genomic hybridization. Int J Cancer 117:95–103
106. Rokes CA, Remke M, Guha-Thakurta N, Witt O, Korshunov A,
Pﬁster S and Wolff JE (2010) Sorafenib plus valproic acid for
infant spinal glioblastoma. J Pediatr Hematol Oncol
107. Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner
DD (2008) Tumor-speciﬁc immunotherapy targeting the EG-
FRvIII mutation in patients with malignant glioma. Semin
Immunol 20:267–275
108. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El
Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre
JY (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an
important prognostic biomarker in gliomas. J Clin Oncol
27:4150–4154
109. Scheie D, Cvancarova M, Mork S, Skullerud K, Andresen PA,
Benestad I, Helseth E, Meling T, Beiske K (2008) Can mor-
phology predict 1p/19q loss in oligodendroglial tumours?
Histopathology 53:578–587
110. Schlosser S, Wagner S, Muhlisch J, Hasselblatt M, Gerss J,
Wolff JE, Fruhwald MC (2010) MGMT as a potential stratiﬁ-
cation marker in relapsed high-grade glioma of children: the
HIT-GBM experience. Pediatr Blood Cancer 54:228–237
111. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diep-
vens F, Pals G (2002) Relative quantiﬁcation of 40 nucleic acid
sequences by multiplex ligation-dependent probe ampliﬁcation.
Nucleic Acids Res 30:e57
112. Seiz M, Tuettenberg J, Meyer J, Essig M, Schmieder K, Mawrin
C, von Deimling A, Hartmann C (2010) Detection of IDH1
mutations in gliomatosis cerebri, but only in tumors with addi-
tional solid component: evidence for molecular subtypes. Acta
Neuropathol 120:261–267
113. Shinojima N, Tada K, Shiraishi S, Kamiryo T, Kochi M, Na-
kamura H, Makino K, Saya H, Hirano H, Kuratsu J, Oka K,
Ishimaru Y, Ushio Y (2003) Prognostic value of epidermal
growth factor receptor in patients with glioblastoma multiforme.
Cancer Res 63:6962–6970
114. Smith JS, Alderete B, Minn Y, Borell TJ, Perry A, Mohapatra G,
Hosek SM, Kimmel D, O’Fallon J, Yates A, Feuerstein BG,
Burger PC, Scheithauer BW, Jenkins RB (1999) Localization of
common deletion regions on 1p and 19q in human gliomas and
their association with histological subtype. Oncogene
18:4144–4152
115. Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ,
Iturria N, O’Fallon JR, Schaefer PL, Scheithauer BW, James
CD, Buckner JC, Jenkins RB (2001) PTEN mutation, EGFR
ampliﬁcation, and outcome in patients with anaplastic astro-
cytoma and glioblastoma multiforme. J Natl Cancer Inst
93:1246–1256
116. Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M,
Yamashita Y, Suzuki H, Tominaga T (2009) Analysis of IDH1
and IDH2 mutations in Japanese glioma patients. Cancer Sci
100:1996–1998
117. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B,
Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U,
Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A,
Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO
(2005) Radiotherapy plus concomitant and adjuvant temozolo-
mide for glioblastoma. N Engl J Med 352:987–996
118. Sugawa N, Ekstrand AJ, James CD, Collins VP (1990) Identical
splicing of aberrant epidermal growth factor receptor transcripts
from ampliﬁed rearranged genes in human glioblastomas. Proc
Natl Acad Sci USA 87:8602–8606
119. Tentori L, Leonetti C, Scarsella M, D’Amati G, Vergati M,
Portarena I, Xu W, Kalish V, Zupi G, Zhang J, Graziani G
(2003) Systemic administration of GPI 15427, a novel poly(-
ADP-ribose) polymerase-1 inhibitor, increases the antitumor
activity of temozolomide against intracranial melanoma, glioma,
lymphoma. Clin Cancer Res 9:5370–5379
120. Toedt G, Barbus S, Wolter M, Felsberg J, Tews B, Blond F,
Sabel MC, Hofmann S, Becker N, Hartmann C, Ohgaki H, von
Deimling A, Wiestler OD, Hahn M, Lichter P, Reifenberger G,
Radlwimmer B (2010) Molecular signatures classify astrocytic
gliomas by IDH1 mutation status. Int J Cancer
121. Trost D, Ehrler M, Fimmers R, Felsberg J, Sabel MC, Kirsch L,
Schramm J, Wiestler OD, Reifenberger G, Weber RG (2007)
Identiﬁcation of genomic aberrations associated with shorter
overall survival in patients with oligodendroglial tumors. Int J
Cancer 120:2368–2376
122. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M,
Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W,
Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC,
Vecht CJ, Allgeier A, Lacombe D, Gorlia T (2006) Adjuvant
procarbazine, lomustine, and vincristine improves progression-
free survival but not overall survival in newly diagnosed ana-
plastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment
of Cancer phase III trial. J Clin Oncol 24:2715–2722
123. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn
MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A,
van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M
(2010) IDH1 and IDH2 mutations are prognostic but not pre-
dictive for outcome in anaplastic oligodendroglial tumors: a
report of the European Organization for Research and Treatment
of Cancer Brain Tumor Group. Clin Cancer Res 16:1597–1604
124. van den Bent MJ, Dubbink HJ, Sanson M, van der Lee-Haarloo
CR, Hegi M, Jeuken JW, Ibdaih A, Brandes AA, Taphoorn MJ,
Frenay M, Lacombe D, Gorlia T, Dinjens WN, Kros JM (2009)
MGMT promoter methylation is prognostic but not predictive
for outcome to adjuvant PCV chemotherapy in anaplastic oli-
godendroglial tumors: a report from EORTC Brain Tumor
Group Study 26951. J Clin Oncol 27:5881–5886
125. van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W,
Graveland W, Uytdewilligen L, Sillevis Smitt PA, Jenkins RB,
Kros JM (2003) Chromosomal anomalies in oligodendroglial
tumors are correlated with clinical features. Cancer
97:1276–1284
126. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilker-
son MD, Miller CR, Ding L, Golub T, Mesirov JP, Alexe G,
Lawrence M, O’Kelly M, Tamayo P, Weir BA, Gabriel S,
Winckler W, Gupta S, Jakkula L, Feiler HS, Hodgson JG, James
CD, Sarkaria JN, Brennan C, Kahn A, Spellman PT, Wilson RK,
Speed TP, Gray JW, Meyerson M, Getz G, Perou CM, Hayes
DN (2010) Integrated genomic analysis identiﬁes clinically
relevant subtypes of glioblastoma characterized by
Acta Neuropathol (2010) 120:567–584 583
123abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell
17:98–110
127. Vlassenbroeck I, Caliﬁce S, Diserens AC, Migliavacca E, Straub
J, Di Stefano I, Moreau F, Hamou MF, Renard I, Delorenzi M,
Flamion B, DiGuiseppi J, Bierau K, Hegi ME (2008) Validation
of real-time methylation-speciﬁc PCR to determine O6-meth-
ylguanine-DNA methyltransferase gene promoter methylation in
glioma. J Mol Diagn 10:332–337
128. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD,
Coller HA, Cross JR, Fantin VR, Hedvat CV, Perl AE, Rabi-
nowitz JD, Carroll M, Su SM, Sharp KA, Levine RL, Thompson
CB (2010) The common feature of leukemia-associated IDH1
and IDH2 mutations is a neomorphic enzyme activity converting
a-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225–234
129. Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1
mutations are early events in the development of astrocytomas
and oligodendrogliomas. Am J Pathol 174:1149–1153
130. Watanabe T, Vital A, Nobusawa S, Kleihues P, Ohgaki H (2009)
Selective acquisition of IDH1 R132C mutations in astrocytomas
associated with Li-Fraumeni syndrome. Acta Neuropathol
117:653–656
131. Weller M, Berger H, Hartmann C, Schramm J, Westphal M,
Simon M, Goldbrunner R, Krex D, Steinbach JP, Ostertag CB,
Loefﬂer M, Pietsch T, von Deimling A (2007) Combined 1p/19q
loss in oligodendroglial tumors: predictive or prognostic bio-
marker? Clin Cancer Res 13:6933–6937
132. Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP,
Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese
O,KrexD,NikkhahG,PietschT,WiestlerO,ReifenbergerG,von
Deimling A, Loefﬂer M (2009) Molecular predictors of progres-
sion-free and overall survival in patients with newly diagnosed
glioblastoma: a prospective translational study of the German
Glioma Network. J Clin Oncol 27:5743–5750
133. Weller M, Stupp R, Reifenberger G, Brandes AA, van den Bent
MJ, Wick W, Hegi ME (2010) MGMT promoter methylation in
malignant gliomas: ready for personalized medicine? Nat Rev
Neurol 6:39–51
134. Weppler SA, Li Y, Dubois L, Lieuwes N, Jutten B, Lambin P,
Wouters BG, Lammering G (2007) Expression of EGFR variant
vIII promotes both radiation resistance and hypoxia tolerance.
Radiother Oncol 83:333–339
135. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J, Stock-
hammer F, Sabel MC, Koeppen S, Ketter R, Meyermann R,
Rapp M, Meisner C, Kortmann RD, Pietsch T, Wiestler OD,
Ernemann U, Bamberg M, Reifenberger G, von Deimling A,
Weller M (2009) NOA-04 randomized phase III trial of
sequential radiochemotherapy of anaplastic glioma with pro-
carbazine, lomustine, and vincristine or temozolomide. J Clin
Oncol 27:5874–5880
136. Wikstrand CJ, Hale LP, Batra SK, Hill ML, Humphrey PA,
Kurpad SN, McLendon RE, Moscatello D, Pegram CN, Reist CJ
et al (1995) Monoclonal antibodies against EGFRvIII are tumor
speciﬁc and react with breast and lung carcinomas and malig-
nant gliomas. Cancer Res 55:3140–3148
137. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan
W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H,
Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu
VE, Vogelstein B, Bigner DD (2009) IDH1 and IDH2 mutations
in gliomas. N Engl J Med 360:765–773
138. Yip S, Iafrate AJ, Louis DN (2008) Molecular diagnostic testing
in malignant gliomas: a practical update on predictive markers.
J Neuropathol Exp Neurol 67:1–15
139. Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, Louis
DN (2009) MSH6 mutations arise in glioblastomas during
temozolomide therapy and mediate temozolomide resistance.
Clin Cancer Res 15:4622–4629
140. Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont
R, Seligson DB, Yong WH, Xiong Z, Rao N, Winther H,
Chakravarti A, Bigner DD, Mellinghoff IK, Horvath S, Cavenee
WK, Cloughesy TF, Mischel PS (2008) Development of a real-
time RT-PCR assay for detecting EGFRvIII in glioblastoma
samples. Clin Cancer Res 14:488–493
141. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, Yu W, Li Z,
Gong L, Peng Y, Ding J, Lei Q, Guan KL, Xiong Y (2009)
Glioma-derived mutations in IDH1 dominantly inhibit IDH1
catalytic activity and induce HIF-1a. Science 324:261–265
584 Acta Neuropathol (2010) 120:567–584
123